HLB TherapeuticsLtd Past Earnings Performance
Past criteria checks 0/6
HLB TherapeuticsLtd's earnings have been declining at an average annual rate of -4.8%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 1.2% per year.
Key information
-4.8%
Earnings growth rate
-1.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -1.2% |
| Return on equity | -1.6% |
| Net Margin | -3.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 38% Share Price Surge Not Quite Adding Up
Apr 11
There's Reason For Concern Over HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Massive 50% Price Jump
Feb 26Does G-treeBNT (KOSDAQ:115450) Have A Healthy Balance Sheet?
Mar 19Did Business Growth Power G-treeBNT's (KOSDAQ:115450) Share Price Gain of 134%?
Dec 21
Revenue & Expenses BreakdownBeta
How HLB TherapeuticsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 53,749 | -1,992 | 15,175 | 0 |
| 30 Sep 23 | 51,078 | -4,390 | 16,519 | 48 |
| 30 Jun 23 | 56,269 | -6,291 | 19,361 | 63 |
| 31 Mar 23 | 47,658 | -9,540 | 15,782 | 63 |
| 31 Dec 22 | 42,403 | -10,823 | 15,130 | 0 |
| 30 Sep 22 | 47,398 | -11,471 | 14,689 | 15 |
| 30 Jun 22 | 41,579 | -10,710 | 10,461 | 0 |
| 31 Mar 22 | 47,116 | -16,905 | 14,407 | 0 |
| 31 Dec 21 | 43,586 | -17,197 | 15,340 | 0 |
| 30 Sep 21 | 46,554 | -16,833 | 15,902 | 0 |
| 30 Jun 21 | 39,427 | -18,287 | 16,174 | 0 |
| 31 Mar 21 | 40,881 | -18,469 | 17,794 | 0 |
| 31 Dec 20 | 42,930 | -16,902 | 17,025 | 0 |
| 30 Sep 20 | 47,746 | -20,618 | 20,812 | 0 |
| 30 Jun 20 | 57,262 | -18,764 | 19,903 | 0 |
| 31 Mar 20 | 59,171 | -14,857 | 16,613 | 0 |
| 31 Dec 19 | 58,966 | -15,975 | 16,448 | 0 |
| 30 Sep 19 | 53,593 | -9,637 | 12,002 | 0 |
| 30 Jun 19 | 53,583 | 1,940 | 10,588 | 0 |
| 31 Mar 19 | 48,233 | 3,653 | 9,524 | 0 |
| 31 Dec 18 | 43,585 | 4,519 | 8,138 | 11 |
| 30 Sep 18 | 33,365 | 6,706 | 5,118 | 300 |
| 30 Jun 18 | 17,023 | -4,010 | 5,403 | 741 |
| 31 Mar 18 | 17,407 | -3,963 | 5,106 | 1,141 |
| 31 Dec 17 | 17,152 | -4,816 | 5,470 | 1,130 |
| 30 Sep 17 | 17,350 | -5,758 | 6,411 | 840 |
| 30 Jun 17 | 17,055 | -5,886 | 6,391 | 400 |
| 31 Mar 17 | 17,083 | -5,995 | 6,882 | 0 |
| 31 Dec 16 | 17,710 | -5,200 | 6,913 | 0 |
| 30 Sep 16 | 17,764 | -4,072 | 5,929 | 403 |
| 30 Jun 16 | 17,796 | -3,825 | 5,897 | 403 |
| 31 Mar 16 | 17,640 | -3,789 | 5,407 | 403 |
| 31 Dec 15 | 16,782 | -4,301 | 5,609 | 403 |
| 30 Sep 15 | 16,406 | -4,381 | 5,380 | 801 |
| 30 Jun 15 | 16,637 | -3,775 | 4,941 | 801 |
| 31 Mar 15 | 16,808 | -3,009 | 4,904 | 801 |
| 31 Dec 14 | 17,618 | -1,346 | 4,200 | 801 |
| 30 Sep 14 | 1,740 | -3,725 | 3,397 | 0 |
| 30 Jun 14 | 12,314 | -4,553 | 4,376 | 0 |
| 31 Mar 14 | 8,337 | -4,536 | 3,701 | 0 |
| 31 Dec 13 | 20,859 | -4,482 | 4,775 | 0 |
| 30 Sep 13 | 46,981 | -1,230 | 5,332 | 0 |
| 30 Jun 13 | 44,025 | -157 | 5,526 | 0 |
Quality Earnings: A115450 is currently unprofitable.
Growing Profit Margin: A115450 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A115450 is unprofitable, and losses have increased over the past 5 years at a rate of 4.8% per year.
Accelerating Growth: Unable to compare A115450's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A115450 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A115450 has a negative Return on Equity (-1.61%), as it is currently unprofitable.